Sildenafil/apixaban
Phase 1Small molecule
Sildenafil/apixaban is one of 41 small molecule programs targeting Pulmonary Embolism. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
81 competitors in Pulmonary Embolism
#DrugCompanyPhaseTrials
1Innohep
Alnylam PharmaceuticalsApproved
Flolan
Johnson & JohnsonApproved
Unfractionated Heparin
GSKApproved
Activase
RochePhase 3
Tnkase
RochePhase 3
Actilyse
Boehringer IngelheimApproved
Heparin Sodium
BBaxter Healthcare Corporation
Phase 3
Low-Molecular-Weight Heparin
Daiichi SankyoPhase 3
Acenocoumarol
RocheApproved
Lovenox
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pulmonary Embolism1 trial
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 1·NCT02946944·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sildenafil/apixaban. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details